Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiagabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 8/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiagabine SCHEMBL41860 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL18496408 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL17493682 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL1527642 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL3272861 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL342814 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL34653 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL7346237 | 0.98 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL3958156 | 0.98 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL3243472 | 0.95 | SLC6A1 (0.90) | SLC6A1PTGS1PDE4AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1331933-B1 | TIAGABINE FOR THE TREATMENT OF DIABETIC NEUROPATHY | ABBOTT LAB (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1331933-A2 | THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE | Abbott Laboratories (US) | 2003-08-06 | — | — | EP | claimed |
| US-20020103236-A1 | Use of tiagabine for treatment of diabetic neuropathy and migraine | ABBVIE INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002038144-A2 | THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE | ABBOTT LABORATORIES (US) | 2002-05-16 | — | — | WO | claimed |
| US-20070212428-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007072471-A2 | NOVEL CRYSTALLINE FORMS OF TIAGABINE HYDROCHLORIDE AND PROCESSES OF PREPARING THE SAME | CHEMAGIS LTD. (IL) | 2007-06-28 | — | — | WO | disclosed |
| EP-1331933-B1 | TIAGABINE FOR THE TREATMENT OF DIABETIC NEUROPATHY | ABBOTT LAB (US) | 2007-03-28 | — | — | EP | disclosed |
| US-6872734-B2 | Use of tiagabine for treatment of diabetic neuropathy and migraine | ABBOTT LABORATORIES (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1331933-A2 | THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE | Abbott Laboratories (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-0906309-B1 | MODIFIED FORM OF THE R(-)-N-(4,4-DI(3-METHYLTHIEN-2-YL)BUT-3-ENYL)-NIPECOTIC ACID HYDROCHLORIDE | NOVO NORDISK AS (DK) | 2002-09-04 | — | — | EP | disclosed |
| US-6399100-B1 | POLYMER MATRIX; ORAL DOSAGE; ANTI-EPILEPTIC DRUG | ELAN CORPORATION, PLC (IE) | 2002-06-04 | — | — | US | disclosed |
| WO-2002038144-A2 | THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE | ABBOTT LABORATORIES (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-0579681-B1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK AS (DK) | 1999-06-02 | — | — | EP | disclosed |
| EP-0906309-A1 | MODIFIED FORM OF THE R(-)-N-(4,4-DI(3-METHYLTHIEN-2-YL)BUT-3-ENYL)-NIPECOTIC ACID HYDROCHLORIDE | NOVO NORDISK A/S (DK) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999006045-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING TIAGABINE | ELAN CORPORATION, PLC (IE) | 1999-02-11 | — | — | WO | disclosed |
| WO-1997047619-A1 | MODIFIED FORM OF THE R(-)-N-(4,4-DI(3-METHYLTHIEN-2-YL)BUT-3-ENYL)-NIPECOTIC ACID HYDROCHLORIDE | NOVO NORDISK A/S (DK) | 1997-12-18 | — | — | WO | disclosed |
| US-5354760-A | Antiepileptic agents; acid-catalyzed hydrolysis of ethyl R-)-N-(4,4-di(3-methylthien-2-yl)but-3-3nyl)nipecotate hydrochloride; crystallization and precipitation from an aqueous solution to form the monohydrate | NOVO NORDISK A/S (DK) | 1994-10-11 | — | — | US | disclosed |
| EP-0579681-A1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992017473-A1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-10-15 | — | — | WO | disclosed |
| US-5010090-A | N-(butenyl substituted) azaheterocyclic carboxylic acids | NOVO NORDISK A/S. (DK) | 1991-04-23 | — | — | US | disclosed |